NCT00651729

Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 279 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity

Conditions

• Stroke
• Muscle Spasticity

Interventions

Type	Name	Description
BIOLOGICAL	Botulinum Toxin Type A	Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg

Timeline

• Start date: 2003-04-01
• Primary completion: 2004-12-01
• Completion: 2004-12-01
• First posted: 2008-04-03
• Last updated: 2008-05-28

Locations

2 sites across 2 countries: United States, Canada